Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts.

Autor:	Ring, J., Worm, M., Wollenberg, A., Thyssen, J.P., Jakob, T., Klimek, L., Bangert, C., Barbarot, S., Bieber, T., Bruin‐Weller, M.S., Chernyshov, P.V., Christen‐Zaech, S., Cork, M., Darsow, U., Flohr, C., Fölster‐Holst, R., Gelmetti, C., Gieler, U., Gutermuth, J., Heratizadeh, A.
Předmět:	COVID-19 vaccines SKIN diseases ALLERGIES MEDICAL personnel ECZEMA PHYSICIANS
Zdroj:	Journal of the European Academy of Dermatology & Venereology; Jun2021, Vol. 35 Issue 6, pe362-e365, 4p
Abstrakt:	Dr. Seneschal has been an investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non-financial support from LEO Pharma, Pierre Fabre, Sanofi-Genzyme and Bioderma. Dr. Vestergaard has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text